# Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS

> **NCT03338114** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Flex Pharma, Inc.**

## Conditions studied

- Amyotrophic Lateral Sclerosis
- Fasciculation

## Interventions

- **DRUG:** FLX-787-ODT (orally disintigrating tablet)

## Key facts

- **NCT ID:** NCT03338114
- **Lead sponsor:** Flex Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-11
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03338114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03338114, "Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03338114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*